Label
Interaction requires management
Color
Yellow
Yellow: Adjust dosing
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Maraviroc ETR 38 | Yellow: Adjust dosing | Adjust dosing to avoid decreased levels of maraviroc | Potential decrease in antiretroviral efficacy |
Maraviroc AUC decreased 53%; Cmin decreased 39% |
200 mg BID | Not reported |
Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID |
| Maraviroc CBZ 37 | Yellow: Adjust dosing | Adjust dosing to avoid decreased levels of maraviroc | Potential decrease in antiretroviral efficacy |
Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID |
|||
| Maraviroc EFV 36 | Yellow: Adjust dosing | Adjust dosing to avoid decreased levels of maraviroc | Maraviroc AUC increased 15%; Cmax increased 16% when compared to maraviroc 100 mg BID given alone. |
600 mg daily | Not reported |
Increase maraviroc dose to 600 mg BID. If including MVC, EFV plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID |
|
| Maraviroc EFV 35 | Yellow: Adjust dosing | Adjust dosing to avoid decreased levels of maraviroc | Potential decrease in antiretroviral efficacy |
Maraviroc AUC decreased 45%; Cmax decreased 51% |
600 mg daily | Not reported |
Increase maraviroc dose to 600 mg BID. If including MVC, EFV plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID |
| Maraviroc RIF 34 | Yellow: Adjust dosing | Adjust dosing to avoid decreased levels of maraviroc | Maraviroc AUC increased 4%; Cmax decreased 3% when compared to maraviroc 100 mg BID given alone. |
600 mg daily | Not reported |
Increase maraviroc dose to 600 mg BID. If also including a strong CYP3A4 inhibitor in the regimen, consider using an alternative agent due to difficulty predicting maraviroc concentrations. |
|
| Maraviroc RIF 33 | Yellow: Adjust dosing | Adjust dosing to avoid decreased levels of maraviroc | Potential decrease in antiretroviral efficacy |
Maraviroc AUC decreased 63%; Cmax decreased 66%; Cmin decreased 78% |
600 mg daily | Not reported |
Increase maraviroc dose to 600 mg BID. If also including a strong CYP3A4 inhibitor in the regimen, consider using an alternative agent due to difficulty predicting maraviroc concentrations. |
| Fostemsavir Rosuvastatin 3 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of rosuvastatin | Increased statin exposure and risk of statin associated adverse events |
Not studied |
10 mg single dose | Cmax increased 78%, AUC increased 69% |
If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events |
| Fostemsavir RFB 2 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of rifabutin | Temsavir Cmax decreased 27%, AUC decreased 30%, Cmin decreased 41% |
300 mg once daily | Not reported |
Use standard dose rifabutin if coadministering with fostemsavir. If using fostemsavir in combination with a ritonavir boosted protease inhibitor, lower rifabutin dose to 150 mg daily. |
|
| Fostemsavir RFB + RTV 1 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of rifabutin | Temsavir Cmax increased 50%, AUC increased 66%, Cmin increased 158% |
RFB 150 mg once daily, RTV 100 mg once daily | Not reported |
Use standard dose rifabutin if coadministering with fostemsavir. If using fostemsavir in combination with a ritonavir boosted protease inhibitor, lower rifabutin dose to 150 mg daily. |
